X

Trial Profile

Long-term Post-Intervention Follow-up of the TODAY Cohort (Treatment Options for Type 2 Diabetes in Youth and Adolescents)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 04 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Metformin (Primary) ; Rosiglitazone (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Acronyms TODAY2

Most Recent Events

29 Jul 2021 Results assessing overall incidence and clustering of complications from TODAY phase1 and phase 2 studies published in the New England Journal of Medicine
10 Aug 2020 Results published in the Diabetes Care
16 Jun 2020 Results (N=381) of oral diabetes medication adherence in the TODAY2 cohort, presented at the 80th Annual Scientific Sessions of the American Diabetes Association

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com